Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer

Abstract

We report a single institution phase I trial of chimeric (mouse-human) monoclonal antibody (chL6) directed against a tumor-associated cell surface antigen expressed in non-small cell lung, colon, and breast cancer. The results of the study were contrasted with a previous trial of murine L6. ChL6 was administered intravenously to 18 patients with advanced cancer as a single, 4-16 infusion in doses ranging from 350 mg/m2 to 700 mg/m2. One patient received four weekly doses of 350 mg/m2. Patients were followed for side effects, localization of antibody to tumor cells, pharmacokinetics and the development of antibodies against chL6. Side effects associated with treatment were chills, fever, and nausea, which lasted 24-48 hours. Platelet count and absolute leukocyte count fell immediately after treatment, but returned to pretreatment levels by day 7. Localization of chL6 to tumor cells in vivo was seen at 350 mg/m2 and "saturation" at 700 mg/m2 and 350 mg/m2 per week x 4. The pharmacokinetics of this antibody appeared similar to its murine analogue. Human antibodies against chL6 were detected in only 4 of 18 patients. These antibodies were directed against murine variable regent and their titers were lower than those occurring in most patients who received murine L6 in an earlier trial. No tumor reductions were seen. Chimeric L6 appears to be a suitable antibody for delivering anti-tumor agents because of its low immunogenicity and favorable in vivo tumor binding characteristics.

Does Paclitaxel (Taxol) Given after 111In-Labeled Monoclonal Antibodies Increase Tumor-Cumulated Activity in Epithelial Cancers?

“…ChL6 is a chimera consisting of a human IgG 1 constant region and the FabV of murine L6. It targets a membrane glycoprotein that is highly expressed on human breast, colon, ovary, and lung carcinomas (21).…”

Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature

“…After overnight incubation at 37 C, 100 mL of culture media containing serial dilutions of ADCs were added. Ninety-six hours later, 50 mL of CellTiter-Glo (Promega) were added to each well and the plates were read for luminescence.…”

“…Tumor cell lines expressing high levels of TM4SF1 were identified with an in silico survey of public and proprietary gene expression databases (CCLE, Oncomine, Gene Logic, and OTP) and from prior publications (7,8,16,37). As a group, NSCLC tumor cell lines expressed the highest levels of TM4SF1 among solid tumors (Fig.…”

Vaccine Development Against Novel Breast Cancer Antigens

“…Immunotherapeutic approaches for the treatment of breast cancer have included the use of monoclonal antibodies and the generation of cytotoxic T lymphocytes (CTL) [1][2][3][4][5][6]. The identification of target antigens, the availability of recombinant proteins and cytokines have given impetus to immunotherapy.…”

“…Spleens cells were tested for reactivity against a panel of overlapping 9-mer peptides representing the VNTR region (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14). Each peptide overlaps by one aminoacid with the next one.…”